Table A1.

Primary and Metastatic Tumor Sites of the International Neuroblastoma Risk Group Analytic Cohort (N = 8,800)

Site	EFS		Patients		5-Year EFS (%)			5-Year OS (%)
	Hazard Ratio	95% CI	No.	%	Rate	SE	Log-Rank P	Rate	SE	Log-Rank P
Primary
Adrenal							< .0001			< .0001
No	1.7	1.6 to 1.8	4,371	52	71	1		78	1
Yes			4,017	48	56	1		62	1
Abdominal							.8657			.9476
No	1.0	0.9 to 1.1	6,296	75	64	1		71	1
Yes			2,093	25	63	1		71	1
Neck							< .0001			< .0001
No	0.5	0.4 to 0.7	8,156	97	63	1		70	1
Yes			255	3	78	3		89	3
Thorax							< .0001			< .0001
No	0.5	0.4 to 0.6	7,036	84	61	1		67	1
Yes			1,372	16	78	1		86	1
Pelvic							< .0001			< .0001
No	0.5	0.4 to 0.6	7,825	97	63	1		70	1
Yes			270	3	80	3		90	2
Other							.0526			.0173
No	0.8	0.7 to 1.0	7,897	94	63	1		70	1
Yes			518	6	68	4		74	4
Metastatic
Bone marrow							< .0001			< .0001
No	3.9	3.6 to 4.2	5,880	70	77	1		85	1
Yes			2,481	30	33	1		39	1
Bone							< .0001			< .0001
No	3.6	3.4 to 3.9	6,487	78	74	1		82	1
Yes			1,860	22	29	1		35	1
Distant lymph node							< .0001			< .0001
No	2.1	1.9 to 2.3	7,101	85	67	1		75	1
Yes			1,214	15	41	2		47	2
Liver							< .0001			< .0001
No	1.3	1.1 to 1.4	7,359	88	64	1		71	1
Yes			1,006	12	59	2		64	2
Skin							.8337			.6095
No	1.0	0.7 to 1.3	7,659	98	66	1		73	1
Yes			155	2	68	5		76	4
Lung							< .0001			< .0001
No	3.1	2.4 to 3.9	7,518	99	66	1		74	1
Yes			102	1	32	7		36	7
CNS							< .0001			< .0001
No	2.6	2.0 to 3.4	7,533	99	66	1		74	1
Yes			87	1	38	6		38	6
Other							< .0001			< .0001
No	2.5	2.3 to 2.8	7,345	88	67	1		75	1
Yes			964	12	36	2		42	2

Abbreviations: EFS, event-free survival; OS, overall survival.